Anti-CTLA-4, anti-PD-1 and anti-PD-L1 Abs were granted approval from the FDA and European Medicines Agency (EMA) for the treatment of a broad spectrum of neoplastic diseases [356], in early and advanced settings, because they were shown to elicit durable clinical responses. Here, CD274 is linked to neoplasm.